LncRNA ZEB2-AS1在卵巢癌组织中的表达水平及临床病理特征与预后的关系

目的:探讨长链非编码核糖核酸（LncRNA）锌指E盒结合同源盒蛋白2-AS1（LncRNA ZEB2-AS1）在卵巢癌组织中的表达水平,并分析其与患者临床病理特征及预后的关系。方法:收集2015年3月至2016年3月本院收治的卵巢癌患者90例为卵巢癌组,同时选取同期于本院体检的健康志愿者52例为对照组。实时荧光定量聚合酶链反应(qRT-PCR)检测LncRNA ZEB2-AS1表达水平。收集患者临床病理资料,根据LncRNA ZEB2-AS1表达水平检测结果将其分为高表达组（52例）与低表达组（38例）,分析其与患者临床病理特征关系。对卵巢癌患者随访3年,采用Kaplan-Meier法分析LncRNA ZEB2-AS1表达与患者预后关系。采用Cox比例风险模型分析影响卵巢癌患者预后的相关因素。结果:卵巢癌患者血清LncRNA ZEB2-AS1表达水平显著高于对照组（P<0.05）;LncRNA ZEB2-AS1表达水平与卵巢癌患者是否发生淋巴结转移、FIGO分期、分化程度及CA125水平明显相关（P<0.05）;Kaplan-Meier法分析显示LncRNA ZEB2-AS1高表达组患者3年无疾病进展生存率与总生存率分别为25.00%、46.88%,LncRNA ZEB2-AS1低表达组患者PFS与OS均显著低于低表达组（P<0.05）;Cox多因素分析显示淋巴结转移、FIGO分期、LncRNA ZEB2-AS1表达均是影响卵巢癌患者预后的独立危险因素（P<0.05）。结论:卵巢癌患者血清LncRNA ZEB2-AS1表达水平明显升高,且与患者临床病理特征及预后密切相关,可能作为卵巢癌早期诊断的标记物及治疗靶点。

Expression of LncRNA ZEB2-AS1 in ovarian cancer and its relationships with clinicopathological features and prognosis

Objective:To investigate the expression of long non-coding ribonucleic acid(LncRNA)zinc finger E-box binding homeobox protein 2-AS1(LncRNA ZEB2-AS1)in ovarian cancer,and to analyze its relationships with clinicopathological characteristics and prognosis.Methods:Ninety patients with ovarian cancer admitted to our hospital from March 2015 to March 2016 were selected as the ovarian cancer group,and fifty-two healthy volunteers were selected as the control group.Real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)was used to detect the expression levels of LncRNA ZEB2-AS1.The clinicopathological data of the patients were collected.According to the results of LncRNA ZEB2-AS1 expression,patients were divided into high expression group(52 cases)and low expression group(38 cases).Its relationship with clinicopathological characteristics was analyzed.Patients with ovarian cancer were followed-up for 3 years.The relationship between the expression of LncRNA ZEB2-AS1 with the prognosis of patients was analyzed by Kaplan-Meier method.Cox proportional hazard model was used to analyze the prognostic factors of ovarian cancer patients.Results:The expression levels of serum LncRNA ZEB2-AS1 in patients with ovarian cancer were significantly higher than those in the control group(P<0.05).The expression level of LncRNA ZEB2-AS1 was significantly correlated with lymph node metastasis,FIGO staging,differentiation and CA125 level in patients with ovarian cancer(P<0.05).Kaplan-Meier analysis showed that PFS and OS were 25.00%and 46.88%respectively of patients in the LncRNA ZEB2-AS1 high expression group,while PFS and OS in the LncRNA ZEB2-AS1 high expression group were significantly lower than those in the low expression group(P<0.05).Cox multivariate analysis showed that lymph node metastasis,FIGO staging and LncRNA ZEB2-AS1 expression were independent risk factors affecting the prognosis of ovarian cancer patients(P<0.05).Conclusion:The expression of serum LncRNA ZEB2-AS1 in patients with ovarian cancer is significantly increased and is closely related to the clinicopathological characteristics and prognosis of the patients.It may serve as a marker for early diagnosis and therapeutic target of ovarian cancer.